Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Clinical trial NCT03483103 · COMPLETED

Trial details

NCT number: NCT03483103
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Non-Hodgkin Lymphoma, Nonhodgkin Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse

Start date: 2018-07-27
Primary completion: 2021-09-24
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.